<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">CABP Due to MRSA and Treatment with Ceftaroline: Experience from the CAPTURE Study</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-17</style></pages><abstract><style  face="normal" font="default" size="100%">There is a need for new antibiotics to treat the rising incidence of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections caused by Gram-positive bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, including the multidrug resistant and methicillin-resistant (MRSA) forms of these bacteria. This article presents a poster [Jandourek et al. ICAAC 2012 L1–300c] with results from the Clinical Assessment Program and Teflaro® Utilization Registry cohort [CAPTURE] study that showed ceftaroline produced good clinical outcomes when used as monotherapy to treat CABP due to MRSA.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>